Answers are grounded in this paper and cite their sources.
DEAR EDITORUveal melanoma (UM) is a rare, aggressive cancer with limited treatment options.Despite significant advancements in understanding its genetic background, 1,2 the precise contribution of epigenomic alterations to the pathogenesis and progression of the disease remain elusive.In this study, we utilized a carefully curated set of UM samples to define the epigenomic and transcriptomic landscapes of high-risk tumours and identify novel, clinically relevant methylation markers and therapeutic targets.We stratified UM patients into risk groups based on UM-specific chromosomal rearrangements, particularly monosomy 3 (M3) and BAP1 mutations in tumour tissues (Figure 1A).Please refer to the Supporting information for a detailed description of patient clinical characteristics and methods (Additional file 1: Tables S1-S3).Specifically, we identified 25 low-risk and 33 high-risk patients, of which 21 (63.6%)carried the BAP1 mutation (Figure 1B, C).We observed extensive gene expression reprogramming in high-risk UMs, resulting in 2262 differentially expressed genes (DEGs) including 60 epigenetic regulators, histone modifiers and chromatin remodelers.Furthermore, we identified 44 398 differentially methylated CpGs, with hypermethylation more frequent in TSS1500 and CpG shores (Supporting Information Additional file 1: Figures S1, S2; Additional file 2: Tables S1-4).Integrative analysis revealed 635 hypomethylated upregulated and 309 hypermethylated downregulated genes in highrisk tumours (Figure 2A,B).A significant proportion of methylation-regulated DEGs belong to specific functional groups, including epigenetic modifiers, transcription factors, tumour suppressor genes and oncogenes (Figure 2C), demonstrating the critical role of DNA methylation in controlling cell fate.The median β values of differentially methylated CpGs, were lower in the high-risk UMs, suggesting that epigenetic gene activation can be more common than repression (Figure 2D).
No takes yet. Share an insight, caveat, or question.
Šoltýsová et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: